3SBIO(01530) plans to offer a 6.50% discount on the rights issue, with a net raise of approximately HK$3.087 billion.

3SBIO (01530) announced that on December 2, 2025 (before trading hours), the company entered into a placing agreement with an exclusive placing agent. As per the agreement, the company has conditionally agreed to place a total of 105 million placing shares to no less than six placees through the exclusive placing agent at a price of HK$29.62 per share. The placing price is HK$29.62 per placing share. The placing price was determined by the company and the exclusive placing agent with reference to the prevailing market price of the shares at the time, representing a discount of 6.50% to the closing market price of HK$31.68 per share on the trading day immediately preceding the date of the placing agreement. Assuming that there have been no changes to the issued share capital between the date of this announcement and the completion, the 105 million placing shares under the placing arrangement would represent approximately 4.14% of the total issued share capital after the issuance of the placing shares. The estimated total proceeds and net proceeds (after deduction of placing commission and other related expenses and professional fees) from the placing are expected to be approximately HK$3.115 billion and HK$3.087 billion, respectively. The company intends to use the net proceeds from the placing as follows: approximately 80% for research and development expenses, including: (a) advancing clinical research in China and the US for innovative drugs in the research stage, including but not limited to 705 (PD1/HER2), 706 (PD1/PDL1), 008 (B7H3/IL15), 59 (MUC17/CD3/CD28), 626 (BDCA2) and 627 (TL1A), (b) supporting the expansion of indications for commercialized drugs or conducting clinical trials outside China to further enhance product value and expand market coverage, including but not limited to TPO and EPO, (c) building global infrastructure and supporting facilities; and approximately 20% for working capital and other general corporate purposes to support the group's ongoing operations and strategic plans.